About the project

EpiPRIME project (Epigenetically Programmed Resilience through Innate Memory Engineering) aims to make cells more resilient to a broad range of viral infections, rather than developing vaccines for specific viral strains, thus aiding efforts for pandemic preparedness.

The EpiPRIME team led by Chiara Herzog have have been awarded a £5.79 million funding from the Advanced Research Institute Agency (ARIA) in June 2026 to explore how epigenetics, the processes that control how genes are switched on and off, can be harnessed to strengthen our immune system’s ability to fight viruses. Launched in 2023, ARIA is UK government’s funding body dedicated in funding moonshot projects; high-risk high-reward scientific research which could fundamentally change the world if successful.

EpiPRIME explanation

Viral infections remain among the most pressing public health and economic challenges worldwide. The COVID-19 pandemic is estimated to have claimed more than 15 million lives and cost the global economy over £10 trillion, while seasonal flu continues to infect a billion people and hospitalise millions every year. Both can also leave lasting health consequences, including heightened risk of autoimmune, neurological and cardiovascular disease.

EpiPRIME aims to tackle this challenge by developing broad prophylactic strategies that boost host resilience rather than targeted approaches to specific viruses and strains. While vaccines have been a major success story of medicine of the 20th century, they fail to keep pace with challenges today’s viruses. This is because vaccines are developed to target the ‘adaptive’ part of the immune system, which aims to prevent specific pathogens. epiPRIME will instead study the ‘innate’ part of the immune system, which rapidly clears viruses and can prevent or curb infections. The team hopes to achieve this by tapping into the body’s ability to create epigenetic ‘memories’ – modifications on top of DNA that switch genes on or off – and will aim to precisely install new memories, essentially upgrading the software of our immune cells so they can recognise and respond to threats they’ve never encountered before.

EpiPRIME team

Funding

EpiPRIME is funded by the Advanced Research + Invention Agency (ARIA).